NASDAQ · ELUT
Elutia Inc
$0.81-$0.00 (-0.42%)
Elutia Inc’s quoted price sits in the lower half of its reported 52-week range, 41.71% below the high.
Loading market information…
NASDAQ · CYTH · USD
Stock price, earnings
Quote as of Mar 26, 2025, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Cyclo Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 55.52% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Upcoming dates and analyst estimates may change. Fiscal quarters follow Cyclo Therapeutics, Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Cyclo Therapeutics, Inc. operates as a clinical-stage biotechnology enterprise focused on developing treatments derived from cyclodextrins for various health conditions. Its flagship therapeutic candidate, Trappsol Cyclo, holds orphan drug status and is presently in Phase III clinical trials targeting Niemann-Pick Type C disease. The company is also investigating Trappsol Cyclo's efficacy in addressing Alzheimer's disease. Beyond its drug development pipeline, the firm engages in the sale of cyclodextrins and related commodities to sectors such as pharmaceuticals and nutrition, primarily for their application in diagnostics and specialized drug formulations. Originally established in 1990 as CTD Holdings, Inc., the company adopted its current name, Cyclo Therapeutics, Inc., in September 2019 and maintains its headquarters in Gainesville, Florida.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 02:31 PM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| $117.12K-36.0% vs estimate |
| Q1 2023 | May 15, 2023 | -$0.46-9.52% vs estimate | $152.41K-59.89% vs estimate |
|---|
| Q4 2022 | Mar 20, 2023 | -$0.59-336.0% vs estimate | $186.80K-70.9% vs estimate |
|---|
THE ANALYST VIEW
3 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
Percentages compare targets with the quoted price when currencies match. Targets are analyst estimates, not guaranteed outcomes.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$0.81-$0.00 (-0.42%)
Elutia Inc’s quoted price sits in the lower half of its reported 52-week range, 41.71% below the high.
$0.71+$0.02 (+2.45%)
HEXO Corp.’s quoted price sits in the lower half of its reported 52-week range, 81.49% below the high.
$0.63$0.00 (0.0%)
LakeShore Biopharma Co., Ltd’s quoted price sits in the lower half of its reported 52-week range, 92.71% below the high.
$0.66$0.00 (0.0%)
Invacare Corporation’s quoted price sits in the lower half of its reported 52-week range, 73.92% below the high.
$5.33$0.00 (0.0%)
Streamline Health Solutions, Inc.’s quoted price sits in the lower half of its reported 52-week range, 43.56% below the high.
$0.21+$0.01 (+5.66%)
Renalytix Plc’s quoted price sits in the lower half of its reported 52-week range, 91.37% below the high.
$0.37-$0.01 (-2.12%)
Elevation Oncology, Inc.’s quoted price sits in the lower half of its reported 52-week range, 88.19% below the high.
$3.07+$0.29 (+10.43%)
MEI Pharma, Inc.’s quoted price sits in the lower half of its reported 52-week range, 65.89% below the high.
